HD Insights: Volume 4

HD Insights: Volume 4

Editor’s Letter

April 1st, 2013 rtullio Welcome to the fourth edition of HD Insights! We started the venture of this periodical in 2011 and we have received great feedback on the first three issues. We electronically distribute every issue to over 1300 investigators, researchers, clinicians, and industry leaders from around the globe. In addition to electronic distribution, in 2011, 300 hard
+ Read More

HD Research Around the World: Japan

April 1st, 2013 rtullio Past, Present, and Future By: Hitoshi Okazawa, MD, PhD Huntington disease (HD) is rare in Japan. Its incidence is one-tenth of that observed in western countries, and as a result, the number of researchers studying HD in Japan is relatively low. Dr. Ichiro Kanazawa, former chair of the Department of Neurology at the University of
+ Read More

Research Round-Up

April 1st, 2013 rtullio By: Lise Munsie, PhD In the lab. . . Future clinical treatments for HD are likely to vary from patient to patient and involve multiple therapies to address all symptoms of the disease. Investigators are seeking to find novel ways to assess HD pathology, and they continue to research the molecular mechanisms of HD. Sathasivam
+ Read More

Lundbeck: Building Hope for HD with Casa De Hogar

April 1st, 2013 rtullio Lundbeck was pleased to donate a large supply of tetrabenazine to the Hereditary Disease Foundation to provide to the Casa De Hogar (House of Love and Hope), a unique clinic in Venezuela that provides care for people affected by HD. The Casa De Hogar clinic provides treatment, food, and care at no cost to thousands
+ Read More

Meet the Compound: Huntexil

April 1st, 2013 rtullio   VITAL SIGNS NAME: Huntexil® (Pridopidine/ACR16) CHEMICAL FORMULA: C15H23NO2S MOLECULAR MASS: 281.41 g/mol. TYPE OF COMPOUND: Dopamine stabilizer MECHANISMS OF ACTION: Functional antagonism of dopamine type 2 receptors and strengthening of cortical glutamate functions in the central nervous system.   Two previous studies that feature Huntexil® are the MermaiHD study and the HART study. The
+ Read More

Meet the Investigator

April 1st, 2013 rtullio VITAL SIGNS NAME: Michael Hayden, CM, OBC, MB, ChB, PhD, FRCP(C), FRSC CURRENT Dr. Michael Hayden was recently appointed as the President of Global Research and Development and Chief Scientific Officer at Teva Pharmaceuticals. Dr. Hayden is the most highly cited author in Huntington disease. He is the founder and director of the Centre for
+ Read More

Meet the Company

April 1st, 2013 rtullio               VITAL SIGNS NAME: Teva Pharmaceutical Industries, Ltd. HEADQUARTERS: Petah Tikva, Israel STOCK PRICE AS OF 3/5/13: $37.25 52 WEEK RANGE: $36.63 – $46.38 MARKET CAPITALIZATION: $31.92B EMPLOYEES: ~46,000 HD INSIGHTS: How did you first become interested in Huntington disease (HD)? MICHAEL HAYDEN: My interest in HD goes back
+ Read More